Report: Responses to Remdesivir Price Mostly Negative
July 1, 2020
Even though the Institute for Clinical for Economic Review (ICER) announced its support of remdesivir’s pricing, the response has been mostly negative, FiercePharma reports.
West Health Policy Center Health Policy Director Sean Dickson said the pricing announcement confirmed a majority of Americans’ concerns that Gilead would take advantage of the pandemic to charge an “unfair” price.
“The American people were right once again – Gilead is using the pandemic to charge an unfair price for remdesivir without sufficient data to demonstrate value,” Dickson wrote in a Twitter post.
To read more on FiercePharma, click here.
